DV
Dividend Vision

ANEB — Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Inc (ANEB)

Total return is -95.5% over the past 5.3 years, 192.9 points behind SPY at 97.4%. Its deepest 1-year drawdown was 100.0%.

Anebulo Pharmaceuticals is a clinical-stage biotechnology company developing treatments for cannabis-related medical conditions, with its lead candidate selonabant currently in phase II clinical trials as a potential antidote for acute cannabinoid intoxication. The company does not currently distribute dividends. Anebulo appeals to investors seeking exposure to early-stage biotech development rather than current income.

ANEB key facts

Asset type
Stock
Asset class
Equity
Inception date
05/07/2021
Last close
$0.32
Market cap
$13,458,962
Average volume
1100.0
Beta
-1.838
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.18